This brand name is authorized in Austria, Australia, Ecuador, Spain, Hong Kong, Israel, Malta, Nigeria, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom
The drug MICROGYNON contains a combination of these active pharmaceutical ingredients (APIs):
|
1
Levonorgestrel
UNII 5W7SIA7YZW - LEVONORGESTREL
|
|
The precise mode of action of levonorgestrel as an emergency contraceptive is not known. At the recommended regimen, levonorgestrel is thought to work mainly by preventing ovulation and fertilisation if intercourse has taken place in the preovulatory phase, when the likelihood of fertilisation is the highest. |
|
2
17 alpha-Ethinylestradiol
UNII 423D2T571U - ETHINYL ESTRADIOL
|
|
Ethinylestradiol is chemically and biologically identical to endogenous human oestradiol. It substitutes for the loss of estrogen production in menopausal women, and alleviates menopausal symptoms. Estrogens prevent bone loss following menopause or ovariectomy. |
Below package inserts are available for further reading:
| Title | Information Source | Document Type | |
|---|---|---|---|
| MICROGYNON Sugar-coated tablets | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| G03AA07 | Levonorgestrel and ethinylestradiol | G Genito urinary system and sex hormones → G03 Sex hormones and modulators of the genital system → G03A Hormonal contraceptives for systemic use → G03AA Progestogens and estrogens, fixed combinations |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: AU | Pharmaceutical Benefits Scheme | Identifier(s): 1456P |
| Country: EC | Agencia Nacional de Regulación, Control y Vigilancia Sanitaria | Identifier(s): 25.012-03-03 |
| Country: ES | Centro de información online de medicamentos de la AEMPS | Identifier(s): 52612, PL00010-0545, PL00010-0545IP, PL00010-0545IP1, R-0600 |
| Country: GB | Medicines & Healthcare Products Regulatory Agency | Identifier(s): 30504, 30526 |
| Country: HK | Department of Health Drug Office | Identifier(s): 43329, 46997 |
| Country: IL | מִשְׂרַד הַבְּרִיאוּת | Identifier(s): 87 |
| Country: MT | Medicines Authority | Identifier(s): AA770/02801 |
| Country: NG | Registered Drug Product Database | Identifier(s): 04-1226 |
| Country: NL | Z-Index G-Standaard, PRK | Identifier(s): 10383, 10502, 554525 |
| Country: NZ | Medicines and Medical Devices Safety Authority | Identifier(s): 2008, 2010, 2012 |
| Country: PL | Rejestru Produktów Leczniczych | Identifier(s): 100043816, 100441959 |
| Country: RO | Agenția Națională a Medicamentului și a Dispozitivelor Medicale | Identifier(s): W64049001 |
| Country: SG | Health Sciences Authority | Identifier(s): 04834P |
| Country: TN | Direction de la Pharmacie et du Médicament | Identifier(s): 8400011 |
| Country: TR | İlaç ve Tıbbi Cihaz Kurumu | Identifier(s): 8699546120024 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
